The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome

Juan Carlos Q. Velez, Florence Wong, K. Rajender Reddy, Arun J. Sanyal, Hugo E. Vargas, Michael P. Curry, Stevan A. Gonzalez, S. Chris Pappas, Khurram Jamil

Research output: Contribution to journalArticlepeer-review

Abstract

Background Hepatorenal syndrome type 1 (HRS-1) - also known as hepatorenal syndrome-AKI (HRS-AKI) - is a rapidly progressing and usually fatal, but potentially reversible, kidney failure occurring in patients with decompensated cirrhosis. A large proportion of patients with HRS-1 require renal replacement therapy (RRT). Terlipressin demonstrated efficacy in reversing HRS and improving renal function in patients with HRS-1 in three phase III, randomized, clinical trials (RCTs; i.e., OT-0401, REVERSE, and CONFIRM). However, these RCTs were not designed to evaluate the effect of terlipressin on the requirement of RRT. In this study, the effect of terlipressin on RRT requirements in the pooled phase III patient population was assessed.MethodsFor this retrospective analysis, data from patients who participated in the OT-0401, REVERSE, and CONFIRM studies were integrated in the largest-to-date randomized database (N=608).ResultsThe need for RRT was significantly decreased in patients in the terlipressin group versus the placebo group by day 30 (28.1% versus 35.9%, respectively; P = 0.040) and day 60 (30.1% versus 37.9%, respectively; P = 0.045) in the pooled population and also postliver transplantation (LT) at day 60 (20.5% versus 40.3%, respectively; P = 0.008) and day 90 (25.3% versus 43.1%, respectively; P = 0.018). More patients were alive and RRT-free by day 90 in the overall population (36.9% versus 28.5%; P = 0.030) and among patients who received an LT (60.0% versus 39.7%; P = 0.010). Random assignment to receive terlipressin was an independent positive predictor of avoidance of RRT (P = 0.042); while higher baseline serum creatinine (sCr) level and Child-Pugh scores were negatively associated with RRT avoidance (P < 0.001 and P = 0.040, respectively).ConclusionsTerlipressin decreased the requirement of RRT compared with placebo among patients with HRS-1, including those receiving LT. A lower sCr level at the beginning of therapy was associated with avoidance of RRT.

Original languageEnglish (US)
Pages (from-to)1030-1038
Number of pages9
JournalKidney360
Volume4
Issue number8
DOIs
StatePublished - Aug 1 2023

Keywords

  • AKI
  • AKI and ICU nephrology
  • ESLD
  • HRS-AKI
  • RRT
  • cirrhosis
  • dialysis
  • hemodialysis
  • renal failure
  • vasoconstrictor

ASJC Scopus subject areas

  • Nephrology
  • Medicine (miscellaneous)
  • General Medicine

Fingerprint

Dive into the research topics of 'The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome'. Together they form a unique fingerprint.

Cite this